Cancer expert doubts claims about prostate cancer trial.

摘要: A leading clinical oncologist has raised questions about claims that a new drug could treat as many 80% of men diagnosed having the most aggressive and previously resistant form prostate cancer. The results phase I trial by Institute Cancer Research Royal Marsden Hospital, showed significant tumour shrinkage big falls in specific antigen (PSA) concentrations 21 with advanced cancer who received abiraterone acetate ( Journal Clinical Oncology 2008 Jul 21; doi: 10.1200/JCO.2007.15.9749). But Nick James, professor oncology at Birmingham University, said it was far …